The Power of Precision: How Coronary CTA and AI Are Reshaping Cardiovascular Medicine
CCTA with plaque analysis and AI-driven fractional flow reserve modeling is redefining how cardiologists detect, treat, and track coronary artery disease. This blog explores how this technology enables earlier intervention, smarter risk assessment, and a more personalized patient experience.
There’s a revolution underway in cardiovascular imaging. For decades, cardiologists have relied on stress tests and invasive procedures to detect and manage coronary artery disease. But now, new tools like coronary computed tomography angiography (CCTA) with AI-powered plaque analysis are providing a clearer, earlier, and more actionable picture of heart health.
In the latest episode of In Circulation, CVL’s podcast exploring the future of cardiology, Dr. Veronica Covalesky (Cardiovascular Consultants of Philadelphia) and Dr. Lance Sullenberger (Capital Cardiology Associates) joined host Jude Hebert, CVL’s VP of Clinical Programs, to unpack the clinical and operational impact of this transformative diagnostic modality.
From Risk Assessment to Actionable Insight
Traditional treadmill stress tests or nuclear single-photon emission computerized tomography (SPECT) provide limited information about whether a patient has coronary artery disease. As Dr. Covalesky explained, “[With] a regular treadmill test, you can’t look them in the eye and say…do I or do I not have it?” Coronary CTA with plaque analysis can give a much clearer answer.
This technology provides a detailed, non-invasive view of total plaque burden, plaque type, and percent stenosis. With these insights, physicians can:
- Identify high-risk non-calcified plaque that may not yet obstruct flow but poses a serious risk
- Personalize therapy based on detailed imaging rather than guideline averages
- Monitor treatment impact and track plaque progression or regression over time
- “Now the goal post for treatment is going to be visual,” said Dr. Covalesky. “It won’t just be a number…it really takes us into a whole different realm.”
A Game Changer for Patient Experience
As both physicians pointed out, patients appreciate visual data. “People like numbers,” said Dr. Sullenberger. “Even if they don’t even fully understand what the number means…they understand why their calcium score may not be as predictive as knowing the total amount of plaque volume.”
This creates a more engaging and effective care experience. When a patient can see their plaque volume or the ratio of calcified to non-calcified plaque, the conversation becomes more meaningful and collaborative.
“[We’re able to say,] ‘You went on a statin and look here, how much you’ve reduced your non-calcified plaque burden,’ which is the most important thing,” Dr. Sullenberger noted. “That motivates patients.”
Enabling Earlier, Smarter Interventions
Beyond diagnosis, the implications of this imaging innovation are profound. When CCTA is used proactively, patients can begin treatment before an acute event occurs. As Dr. Covalesky explained, “We’re sending lots of patients to the cath lab who really don’t need to go. So, this is like the birth of a new dawn…with fancier tools that give you more precision, so your patients get an immediate answer.”
For patients with non-obstructive disease or symptoms that don’t align with traditional markers, CCTA offers a more detailed explanation. It also opens the door to medication intensification, even when low-density lipoprotein (LDL) cholesterol appears to be well-controlled.
“Despite your LDL being ‘at goal,’ per the guidelines, we need to be more aggressive,” said Dr. Sullenberger. “I’ll put that patient on a PCSK9 inhibitor to try to drive their LDLs down.”
A Platform for Innovation
Capital Cardiology was an early adopter of AI-driven CTA, partnering with Cleerly to feed data and watch the technology evolve.
Over time, the AI models improved dramatically, allowing the clinical team to:
- Identify plaque that the human eye could not
- Validate findings against AI to enhance accuracy
- Understand which lesions might be ischemic using non-invasive modeling
“The machine picks up on plaque that your naked eye can’t see,” said Dr. Sullenberger. “Every six months, it was getting a little bit better…[and] I learned a ton from just being a part of that experience, about how good AI is at continuing to learn…as it gets more and more data.”
This collaboration helped embed AI into their daily workflow and turn it from a research initiative into an integral part of patient care.
What Comes Next for CCTA?
Both physicians agreed that AI will increasingly support multimodality imaging. From positron emission tomography/computed tomography (PET/CT) to echo and electronic medical record (EMR) systems, AI is poised to influence diagnosis, documentation, and clinical decision-making in the coming years.
“Ultimately, what’s going to happen is…there’s going to be an overlay AI that’s going to integrate all the information and help the clinician sort what the next best test is,” said Dr. Covalesky.
Clinical Advice for Adopting CCTA + AI-Powered Plaque Analysis
Dr. Covalesky and Dr. Sullenberger offered guidance to cardiologists and APPs who are navigating this shift:
- Find your AI champion. Partner with a colleague who understands the technology and can help you interpret early reports.
- Get educated. There are excellent free and vendor-sponsored resources to learn about AI-generated plaque reports.
- Advocate for access. Even if your practice has CCTA, not all sites use plaque analysis or FFR. Push for broader access.
- Use the data. As Dr. Covalesky noted, clinicians should not assume a zero-calcium score means zero risk. , patients, and peers that your practice is delivering accountable, evidence-based care.
A Call to Embrace the Future
The biggest obstacle to adoption isn’t technology. It’s mindset and willingness to adapt. As demand for cardiovascular care rises and the physician workforce shrinks, tools like CCTA and AI will be essential to delivering high-quality, cost-effective patient care.
“This plaque analysis gets down so granularly to what is wrong with the patient and what they need,” said Dr. Covalesky. “It will allow you to target the therapies very specifically and very, very much affect their prognosis.”
Contact CVL to explore how we can help your practice bring these tools to life and impact patient care.
FAQs: Understanding Coronary CTA, Plaque Analysis, and AI in Cardiology
What is coronary CTA with plaque analysis, and how is it different from a traditional stress test?
Coronary computed tomography angiography (CCTA) with plaque analysis provides a non-invasive, high-resolution view of the coronary arteries, showing plaque burden, plaque type, and degree of stenosis. Unlike treadmill or SPECT stress tests, which only infer ischemia, CCTA helps physicians directly visualize and measure disease—even before symptoms or flow obstruction occur.
How does artificial intelligence (AI) improve the accuracy and utility of CCTA?
AI models can detect subtle plaque patterns and quantify total plaque volume down to cubic millimeter levels, including non-calcified and low-density plaque that may be missed by the human eye. This enhances diagnostic precision and helps guide personalized treatment decisions.
Why is non-obstructive plaque still important in assessing cardiovascular risk?
Even when plaque does not yet block blood flow, its presence—especially non-calcified, low-density plaque—can signal higher risk of acute coronary events. Identifying and monitoring this plaque allows clinicians to intensify therapy and prevent progression.
How are cardiology practices using CCTA and AI in everyday clinical care?
Clinicians use these tools to identify early disease, guide decisions on statin or PCSK9 therapy, monitor treatment effectiveness through serial imaging, and avoid unnecessary invasive procedures. Many practices now consider CCTA with AI a frontline tool for evaluating symptomatic and at-risk patients.
Is CCTA covered by insurance, and what are the barriers to adoption?
Coverage is improving, particularly as payers recognize the value of CCTA with FFR and plaque analysis in reducing unnecessary catheterizations and improving outcomes. Remaining barriers include training, equipment investment, and integration into workflows—but physician demand and platform support are helping practices overcome them.
🎧 Want more insights from leading cardiologists and industry experts? Tune in to the In Circulation podcast to hear how cardiology leaders are shaping the future of outpatient care.
The Future of Cardiovascular Care Is Outpatient: Why Now Is the Time to Build ASC Infrastructure
Outpatient cardiovascular care is growing fast. This blog explores why practices are shifting to ASCs, what’s driving patient and payer...
Achieve More Impactful Practice Enhancements by Joining a Cardiovascular Platform
Premier cardiologists don’t want to get bogged down in administrative work that takes time and attention away from patient care....